Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-05
1999-11-09
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514407, 514520, 514521, 514523, 514525, 5483717, 548494, 558390, 558393, 558397, 558401, A61K 31275, A61K 3140, A61K 31415, C07C31728
Patent
active
059815698
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLK-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described. The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5063243 (1991-11-01), Cho et al.
patent: 5124354 (1992-06-01), Green
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5281619 (1994-01-01), Dell et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
Yaish et al., "Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors", Science, vol. 242(4880), pp. 933-935, Nov. 1988.
Ohmichi et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellr Actions of Nerve Growth Factor", Biochemistry, vol. 32(17), pp. 4650-4658, Apr. 1993.
Mazumder et al., Biochemistry (1995) 34(46), 15111-15122, 1995.
Posner et al., Molecular Pharmacology (1994), 45(4), 673-83, 1994.
Gazit, Aviv et al., "Tyrphostins. 2. Heterocyclic and .alpha.-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2
eu Tyrosine Kinases", Journ. Med. Chem., 34:1896-1907 (1991).
Gazit, Aviv et al., "Tyrphostins. 3. Structure-Activity relationship Studies of .alpha.-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins", J. Med. Chem., 36:3556-3564 (1993).
Kokosi, Jozsef et al., "Process for producing imidazo[5,1-b]quinazolin-9-one derivatives and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising such as active ingredient", Chemical Abstracts, vol. 117, abstract No. 212519, (1990).
Merlin, Jean Claude et al., "Resonance Raman study of phenylhydrazonopropanedinitriles", Can. J. Chem., 63:1840-1844 (1985).
Miyoshi, Hideto et al., "Quantitative analyses of the uncoupling activity of substituted phenols with mitochondria from flight muscles of house flies", Biochimica et Biophysica Acta, 935:312-321 (1988).
Ohmichi, Masahide et al., "The Tyrokinase Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor", Biochemistry, 32:4650-4658 (1993).
Stout, David M. et al., "Synthesis and Antiarrhythmic and Parasympatholytic Properties of Substituted Phenols. 1. Heteroarylamine Derivatives", J. Med. Chem., 26:808-813 (1983).
Vogel, M. et al., "Synthese von-4-substituierten 1,2,3-Triazolo[1,5-a]-chinoxalinen.sup.2)", Journal f. prakt. Chemie: Band 329, Heft 1:101-107 (1987).
Anafi, M. et al., 1992, "Selective Interactions of Transforming and Normal abl Proteins with ATP, Tyrosine-Coploymer Substrates, and Tyrphostins", J. Biol. Chem. 267(7):4518-4523.
Arvidsson, A. et al., 1994, "Tyr-716 in the Platelet-Derived Growth Factor .beta.-Receptor Kinase Insert Is Involved in GRB2 Binding and Ras Activation", Molec. and Cell. Biol. 14(10):6715-6726.
Bolen, J.B., 1993, "Nonreceptor tyrosine protein kinases", Oncogene 8:2025-2031.
Breier, G. et al., 1992, "Expression of vascular endothelial growth factor during embryonic angiogenesis and andothelial cell differentiation", Development 114:521-532.
Brunton, V.G. et al., 1994, "Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor", Anti-Cancer Drug Design 9:311-329.
De Vries C. et al., 1992, "The fms-Like Tyrosine Kinase, a Recpetor for Vascular Endothelial Growth Factor", Reports 21:989-991.
Fantil, W.J. et al., 1992, "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways", Cell 69:413-423.
Folkman, M.J., "Antiangiogenesis", Lippincott, Alternative Strategies for Biol. Therapy, pp. 743-753, 1991.
Houck, K.A. et al., 1992, "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms", J. Biol. Chem. 267(36):26031-26037.
Hu, P. et al., 1992, "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors", Molec. and Cell. Biol. 12(3):981-990.
Jellinek, D. et al., 1994, "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor", Biochemistry 33:10450-10456.
Kashishian, A. & Cooper, J.A., 1993, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C.tau.1", Molec. Biol. 4:49-57.
Kashishian, A. et al., 1992, "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and Pl3 kinase in vivo", EMBO J. 11(4):1373-1382.
Kaur, G. et al., 1994, "Tyrphostin induced growth inhibition: correlation with effect on p210.sup.bcr-abl autokinase activity in K562 chronic myelogenous leukemia", Anti-Cancer Drugs 5:213-222.
Kendall, R.L., 1993, "Inhibition of vascular endothelial cell grwoth factor activity by an endogenously encoded soluble receptor", PNAS USA 90:10705-10709.
Kim, K.J. et al., 1993, "Inhibition of vascular endothelial grwoth factor-induced angiogenesis suppresses tumor growth in vivo", Nature 362(29):841-844.
Kinsella, J.L. et al., 1992, "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel", Exper. Cell Res. 199:56-62.
Klagsbrun, M. & Soker, S., 1993, "VEGF/VPF: the angiogenesis factor found?", Current Biol. 3(10):699-702.
Koch, A.C. et al., 1991, "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins", Science 252:668-674.
Kondo, S. et al., 1993, "Significance of Vascular Endothelial Grwoth Factor/Vascular Permeability Factor for Solid Tumor Growth, and its Inhibition by the Antibody", Biochem. Biophys. Res. Comm. 194(3):1234-1241.
Liotta, L. et al., 1991, "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation", Cell 64:327-336.
Maglione, D. et al., 1991, "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor", PNAS USA 88:9267-9271.
Maglione, D. et al., 1993, "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14", Oncogene 8:925-931.
Mariani, M. et al., 1994, "Inhibition of Angiogenesis by FCE 26806, A Potent Tyronase Kinase Inhibitor", Proc. of the Am. Assoc. for Cancer Res. 35:381 #2268.
Matthews, W. et al., 1991, "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit", PNAS USA 88:9026-9030.
Millauer, B. et al., 1993, "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis", Cell 72:835-846.
Millauer, B. et al., 1994, "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", Nature 367:576-579.
Nishimura, R. et al., 1993, "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor", Molec. Cell Biol. 13(11):6889-6896.
Oelrichs, R.B. et al., 1993, "NYK/FLK-1: A putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo", Oncogene 8:11-18.
Plate, K.H. et al., 1993, "Up-Regulation of Vascular Endothelial Growth Factor and its Cognate Receptors in a Ra
App Harald
Gazit Aviv
Levitzki Alexander
McMahon Gerald M.
Tang Peng Cho
Raymond Richard L.
Sugen Inc.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Substituted phenylacrylonitrile compounds and compositions there does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenylacrylonitrile compounds and compositions there, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenylacrylonitrile compounds and compositions there will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456599